| #1 | Gamma entrainment therapy to restore hippocampal-cortical synchrony | SST | 0.681 | $0.80 | SDA-2026-04-03-26abc |
| #2 | Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation | BDNF | 0.677 | $0.51 | SDA-2026-04-03-26abc |
| #3 | Nutrient-Sensing Epigenetic Circuit Reactivation | SIRT1 | 0.670 | $0.77 | SDA-2026-04-04-gap-e |
| #4 | Transcriptional Autophagy-Lysosome Coupling | FOXO1 | 0.665 | $0.72 | sda-2026-04-01-gap-0 |
| #5 | Selective Acid Sphingomyelinase Modulation Therapy | SMPD1 | 0.648 | $0.76 | SDA-2026-04-01-gap-l |
| #6 | CYP46A1 Overexpression Gene Therapy | CYP46A1 | 0.631 | $0.75 | SDA-2026-04-01-gap-l |
| #7 | APOE-Dependent Autophagy Restoration | MTOR | 0.615 | $0.66 | sda-2026-04-01-gap-a |
| #8 | Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) | APOE | 0.595 | $0.54 | sda-2026-04-01-gap-0 |
| #9 | Circadian-Synchronized Proteostasis Enhancement | CLOCK/ULK1 | 0.584 | $0.53 | sda-2026-04-01-gap-0 |
| #10 | Microbial Inflammasome Priming Prevention | NLRP3, CASP1, IL1B, PYCARD | 0.584 | $0.48 | SDA-2026-04-01-gap-2 |
| #11 | PARP1 Inhibition Therapy | PARP1 | 0.575 | $0.52 | sda-2026-04-01-gap-0 |
| #12 | TFEB Nuclear Translocation to Reset Lysosomal-Hypoxia Axis | TFEB, MTOR | 0.575 | $0.57 | SDA-2026-04-13-gap-p |
| #13 | AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses | PRKAA1 | 0.570 | $0.66 | sda-2026-04-01-gap-v |
| #14 | ER Stress Reduction as Adjunctive Therapy to Support Autophagy | HFE (H63D variant) | 0.566 | $0.57 | SDA-2026-04-15-gap-p |
| #15 | Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation | FCGRT | 0.566 | $0.56 | sda-2026-04-01-gap-0 |
| #16 | Synthetic Biology BBB Endothelial Cell Reprogramming | TFR1, LRP1, CAV1, ABCB1 | 0.565 | $0.55 | sda-2026-04-01-gap-0 |
| #17 | Chromatin Accessibility Restoration via BRD4 Modulation | BRD4 | 0.559 | $0.54 | SDA-2026-04-04-gap-e |
| #18 | PIKFYVE Inhibition Activates Aggregate Exocytosis via PI(3,5)P2→TRPML1→Calcineurin→TFEB Cascade in ALS Motor Neurons | PIKFYVE/MCOLN1/PPP3CB/TFEB | 0.559 | $0.56 | SDA-2026-04-13-gap-p |
| #19 | Circadian Clock-Autophagy Synchronization | CLOCK | 0.547 | $0.56 | sda-2026-04-01-gap-v |
| #20 | Circadian Glymphatic Rescue Therapy (Melatonin-focused) | MTNR1A | 0.546 | $0.56 | sda-2026-04-01-gap-v |
| #21 | Senescent Cell Mitochondrial DNA Release | CGAS/STING1/DNASE2 | 0.545 | $0.53 | sda-2026-04-01-gap-0 |
| #22 | APOE4 Allosteric Rescue via Small Molecule Chaperones | APOE | 0.542 | $0.55 | sda-2026-04-01-gap-0 |
| #23 | HDAC6 Activation as SCFA-Mediated Neuroprotective Mechanism | HDAC6, HSP90AA1 | 0.537 | $0.55 | SDA-2026-04-12-gap-d |
| #24 | C9orf72-SMCR8-WDR41 Complex Dysfunction in C9-ALS Rescued by PIKFYVE Inhibition via Lysosomal Exocytosis Restoration | C9orf72/SMCR8/RAB7A/PIKFYVE | 0.537 | $0.54 | SDA-2026-04-13-gap-p |
| #25 | Targeted APOE4-to-APOE3 Base Editing Therapy | APOE | 0.526 | $0.53 | sda-2026-04-01-gap-0 |
| #26 | Phase-Separated Organelle Targeting | G3BP1 | 0.521 | $0.53 | sda-2026-04-01-gap-0 |
| #27 | TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimination Through Type I IFN Hyperactivation | TBK1 | 0.520 | $0.52 | SDA-2026-04-13-gap-p |
| #28 | Cell-Type Specific TREM2 Upregulation in DAM Microglia | TREM2 | 0.519 | $0.49 | analysis-SEAAD-20260 |
| #29 | GFAP-Positive Reactive Astrocyte Subtype Delineation | GFAP | 0.518 | $0.48 | analysis-SEAAD-20260 |
| #30 | Heat Shock Protein 70 Disaggregase Amplification | HSPA1A | 0.511 | $0.52 | sda-2026-04-01-gap-0 |
| #31 | Senescence-Associated Myelin Lipid Remodeling | PLA2G6/PLA2G4A | 0.511 | $0.48 | sda-2026-04-01-gap-0 |
| #32 | SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction | SIRT3 | 0.509 | $0.36 | SDA-2026-04-03-gap-s |
| #33 | TREM2-SYK Signaling Axis Couples OxPC Recognition to Phagocytic Clearance | TREM2 (Triggering receptor expressed on myeloid cells 2) + SYK (spleen tyrosine kinase) | 0.505 | $0.51 | SDA-2026-04-13-gap-p |
| #34 | Vocal Cord Neuroplasticity Stimulation | CHR2/BDNF | 0.498 | $0.51 | sda-2026-04-01-gap-0 |
| #35 | Ganglioside Rebalancing Therapy | ST3GAL2/ST8SIA1 | 0.496 | $0.51 | SDA-2026-04-01-gap-l |
| #36 | Autophagosome Maturation Checkpoint Control | STX17 | 0.494 | $0.50 | sda-2026-04-01-gap-0 |
| #37 | Stress Granule Phase Separation Modulators | G3BP1 | 0.490 | $0.50 | sda-2026-04-01-gap-v |
| #38 | Lysosomal Calcium Channel Modulation Therapy | MCOLN1 | 0.489 | $0.50 | sda-2026-04-01-gap-0 |
| #39 | Lysosomal Enzyme Trafficking Correction | IGF2R | 0.489 | $0.50 | sda-2026-04-01-gap-0 |
| #40 | Transglutaminase-2 Cross-Linking Inhibition Strategy | TGM2 | 0.488 | $0.49 | sda-2026-04-01-gap-9 |
| #41 | Orexin-Microglia Modulation Therapy | HCRTR2 | 0.488 | $0.50 | sda-2026-04-01-gap-v |
| #42 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.487 | $0.47 | SDA-2026-04-04-gap-t |
| #43 | Metabolic Switch Targeting for A1→A2 Repolarization | HK2 | 0.481 | $0.49 | sda-2026-04-01-gap-0 |
| #44 | RNA Granule Nucleation Site Modulation | G3BP1 | 0.479 | $0.49 | sda-2026-04-01-gap-0 |
| #45 | Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting | HTT, DMPK, repeat-containing transcripts | 0.479 | $0.44 | SDA-2026-04-03-gap-c |
| #46 | Astrocyte-Mediated Neuronal Epigenetic Rescue | HDAC | 0.479 | $0.49 | SDA-2026-04-04-gap-e |
| #47 | Metabolic Circuit Breaker via Lipid Droplet Modulation | PLIN2 | 0.476 | $0.48 | sda-2026-04-01-gap-0 |
| #48 | Circadian-Gated Maresin Biosynthesis Amplification | ALOX12 | 0.471 | $0.48 | sda-2026-04-01-gap-0 |
| #49 | Sphingomyelin Synthase Activators for Raft Remodeling | SGMS1/SGMS2 | 0.468 | $0.48 | SDA-2026-04-01-gap-l |
| #50 | Arginine Methylation Enhancement Therapy | PRMT1 | 0.463 | $0.47 | sda-2026-04-01-gap-0 |
| #51 | Lipid Droplet Dynamics as Phenotype Switches | DGAT1 and SOAT1 | 0.463 | $0.47 | sda-2026-04-01-gap-0 |
| #52 | HDAC3-Selective Inhibition for Clock Reset | HDAC3 | 0.459 | $0.47 | sda-2026-04-01-gap-v |
| #53 | Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy | ALOX15 | 0.455 | $0.46 | sda-2026-04-01-gap-0 |
| #54 | Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits | PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes | 0.451 | $0.46 | SDA-2026-04-03-gap-c |
| #55 | Lysosomal Membrane Repair Enhancement | CHMP2B | 0.449 | $0.46 | sda-2026-04-01-gap-0 |
| #56 | Microbial Metabolite-Mediated α-Synuclein Disaggregation | SNCA, HSPA1A, DNMT1 | 0.448 | $0.46 | SDA-2026-04-01-gap-2 |
| #57 | Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution | GPR37 | 0.447 | $0.46 | sda-2026-04-01-gap-0 |
| #58 | MITF Acts as the Primary Transcriptional Effector Downstream of HDAC1/2 Deletion, Driving the DAM2 Lysosomal Program Through De-repression of Phagocytic Enhancers | MITF | 0.444 | $0.44 | SDA-2026-04-13-gap-p |
| #59 | Sphingolipid Metabolism Reprogramming | CERS2 | 0.443 | $0.45 | sda-2026-04-01-gap-0 |
| #60 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.442 | $0.43 | SDA-2026-04-04-gap-t |
| #61 | Enteric Nervous System Prion-Like Propagation Blockade | TLR4, SNCA | 0.440 | $0.45 | SDA-2026-04-01-gap-2 |
| #62 | APOE Isoform Conversion Therapy | APOE | 0.437 | $0.45 | sda-2026-04-01-gap-a |
| #63 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.437 | $0.45 | SDA-2026-04-04-gap-t |
| #64 | Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation | KCNK2 | 0.437 | $0.45 | sda-2026-04-01-gap-v |
| #65 | TREM2-Mediated Selective Aggregate Clearance Pathway | TREM2 | 0.430 | $0.44 | sda-2026-04-01-gap-9 |
| #66 | Mitochondrial-Lysosomal Contact Site Engineering | RAB7A | 0.430 | $0.44 | sda-2026-04-01-gap-0 |
| #67 | Lysosomal Positioning Dynamics Modulation | LAMP1 | 0.430 | $0.44 | sda-2026-04-01-gap-0 |
| #68 | Glycine-Rich Domain Competitive Inhibition | TARDBP | 0.429 | $0.44 | sda-2026-04-01-gap-0 |
| #69 | R-Loop Resolution Enhancement Therapy | SETX | 0.428 | $0.44 | sda-2026-04-01-gap-v |
| #70 | Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring | Disease-causing mutations with integrated reporters | 0.423 | $0.43 | SDA-2026-04-03-gap-c |
| #71 | Flotillin-1 Stabilization Compounds | FLOT1 | 0.422 | $0.43 | SDA-2026-04-01-gap-l |
| #72 | HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor | DNAJB6 | 0.420 | $0.43 | sda-2026-04-01-gap-9 |
| #73 | PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria | BNIP3/BNIP3L | 0.418 | $0.43 | sda-2026-04-01-gap-2 |
| #74 | VCP-Mediated Autophagy Enhancement | VCP | 0.415 | $0.42 | SDA-2026-04-04-gap-t |
| #75 | Microbiome-Derived Tryptophan Metabolite Neuroprotection | AHR, IL10, TGFB1 | 0.408 | $0.42 | SDA-2026-04-01-gap-2 |
| #76 | Palmitoylation-Targeted BACE1 Trafficking Disruptors | BACE1 | 0.407 | $0.42 | SDA-2026-04-01-gap-l |
| #77 | Partial Neuronal Reprogramming via Modified Yamanaka Cocktail | OCT4 | 0.399 | $0.41 | SDA-2026-04-04-gap-e |
| #78 | Ephrin-B2/EphB4 Axis Manipulation | EPHB4 | 0.399 | $0.41 | sda-2026-04-01-gap-0 |
| #79 | The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction | TFEB | 0.398 | $0.41 | SDA-2026-04-02-gap-v |
| #80 | TFEB-PGC1α Mitochondrial-Lysosomal Decoupling | TFEB | 0.398 | $0.41 | SDA-2026-04-03-gap-a |
| #81 | The Glial Ketone Metabolic Shunt Hypothesis | HMGCS2 | 0.398 | $0.41 | SDA-2026-04-02-gap-v |
| #82 | SIRT6-NAD+ Axis Enhancement Therapy | SIRT6 | 0.395 | $0.40 | sda-2026-04-01-gap-v |
| #83 | FOXO3-Longevity Pathway Epigenetic Reprogramming | FOXO3 | 0.386 | $0.40 | sda-2026-04-01-gap-v |
| #84 | Metabolic Reprogramming via Microglial Glycolysis Inhibition | HK2 | 0.385 | $0.39 | sda-2026-04-01-gap-v |
| #85 | Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption | PHB2 | 0.384 | $0.39 | sda-2026-04-01-gap-9 |
| #86 | Nucleolar Stress Response Normalization | NPM1 | 0.378 | $0.39 | sda-2026-04-01-gap-v |
| #87 | Optogenetic Control of Mitochondrial Transfer Networks | ChR2 | 0.378 | $0.39 | sda-2026-04-01-gap-2 |
| #88 | RNA-Binding Competition Therapy for TDP-43 Cross-Seeding | TARDBP | 0.374 | $0.38 | sda-2026-04-01-gap-9 |
| #89 | Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery | RAB27A/LAMP2B | 0.370 | $0.38 | sda-2026-04-01-gap-2 |
| #90 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.340 | $0.35 | SDA-2026-04-04-gap-t |
| #91 | Netrin-1 Gradient Restoration | NTN1 | 0.327 | $0.34 | sda-2026-04-01-gap-0 |